What was the impact of the Hospira spin-off on Abbott's financial statements?

The income and cash flows of Hospira, along with direct transaction costs of the spin-off, have been presented as discontinued operations in the Condensed Consolidated Statement of Earnings and Statement of Cash Flows for the periods presented. Prior years' balance sheets were not adjusted. Assets and liabilities related to Hospira's international business that are still being transferred are presented as assets and liabilities held for sale as of September 30, 2004.

How did recent acquisitions affect Abbott's financial results?

Abbott made significant acquisitions in 2004, including TheraSense, Inc. for $1.2 billion and i-STAT Corporation for $394 million, primarily in the diagnostics sector. These acquisitions contributed to an increase in intangible assets and goodwill. They also resulted in charges for acquired in-process research and development. The company noted that these acquisitions, along with others, contributed to increased sales in their respective segments.

What are the key legal and regulatory matters facing Abbott?

Abbott is involved in various legal proceedings, including antitrust suits related to pharmaceutical pricing and patent settlements (e.g., Hytrin). The company also reported an agreement in principle to settle allegations concerning TAP Pharmaceutical Products Inc.'s marketing and pricing of Lupron, with Abbott's portion included in its legal reserves. While management believes the ultimate disposition of these matters will not have a material adverse effect, reserves of approximately $160 million have been recorded for potential losses ranging from $130 million to $225 million.

How did foreign currency fluctuations impact Abbott's results?

The relatively weaker U.S. dollar had a positive impact on Abbott's international sales and overall consolidated net sales. For the third quarter of 2004, the weaker dollar increased consolidated net sales by 1.8% and International segment sales by 4.0% compared to the prior year. For the first nine months, the impact was 3.5% and 8.0%, respectively.

ABT 10-Q Quarterly Report Q3 FY2004 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' (ABT) third quarter 2004 results show robust top-line growth, with net sales increasing by 10.2% to $4.68 billion compared to the prior year. This growth was driven by strong performance across its Pharmaceutical, Diagnostics, and International segments. Net earnings also saw a significant increase, rising to $804.1 million from $761.2 million in the same period last year, leading to a diluted EPS of $0.51, up from $0.48. The company has also been active on the strategic front, completing significant acquisitions in the diagnostics and nutritionals space, including the notable $1.2 billion acquisition of TheraSense, Inc., a leader in blood glucose monitoring systems. The company successfully spun off its Hospital Products segment into a new entity, Hospira, Inc., in April 2004. This strategic move is intended to allow Abbott to focus on its core businesses. Despite increased R&D spending to support pipeline programs and integration costs from acquisitions, Abbott demonstrated improved operating earnings and maintained a strong cash flow from operations, indicating a healthy financial position. The company also reaffirmed its full-year EPS guidance, signaling confidence in its continued performance.

Key Highlights

1Net sales grew 10.2% year-over-year to $4.68 billion for the third quarter.
2Net earnings increased to $804.1 million, with diluted EPS reaching $0.51.
3Completed the spin-off of Hospira, Inc. on April 30, 2004, to focus on core businesses.
4Acquired TheraSense, Inc. for approximately $1.2 billion in April 2004 to bolster its diabetes care offerings.
5Research and development expenses increased 4.9% for the first nine months, driven by pipeline development.
6Operating earnings showed significant improvement, up from $820.8 million in Q3 2003 to $1,022.5 million in Q3 2004.
7The company reaffirmed its full-year earnings per share guidance.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2004

Summary

Key Highlights

Frequently Asked Questions